Stock events for Rapid Micro Biosystems, Inc. (RPID)
Over the past six months, RPID's stock price has increased by 70.95%, but recently fell by -7.62% compared to the previous week and -4.41% over the last month. Key events include Q3 2025 financial results exceeding expectations with a revenue of $7.8 million, a record multi-system customer order, a global distribution agreement with MilliporeSigma, and preliminary Q4 2025 revenue results of approximately $11.3 million. The CEO recently sold US$149k worth of stock. Rapid Micro Biosystems announced inducement equity awards to three newly hired employees. The company is scheduled to release its fourth quarter and full year 2025 financial results on March 12, 2026.
Demand Seasonality affecting Rapid Micro Biosystems, Inc.’s stock price
There is some variability in the demand for Rapid Micro Biosystems' products and services. Q4 2025 consumables revenue was expected to decrease sequentially to be consistent with Q2 levels due to the timing of customer orders and shipments. Service revenue was also anticipated to temporarily decrease in Q4. While overall demand is accelerating, there can be quarterly fluctuations in specific revenue streams due to customer purchasing patterns and project timelines.
Overview of Rapid Micro Biosystems, Inc.’s business
Rapid Micro Biosystems, Inc. (RPID) is a life sciences technology company providing automated solutions for microbial contamination detection in healthcare product manufacturing. Operating in the Healthcare sector, specifically Healthcare Equipment & Supplies, and categorized under Producer Manufacturing and Industrial Machinery, its core business revolves around the Growth Direct® platform. This platform automates manual microbial quality control (MQC) testing workflows and includes the Growth Direct system, proprietary consumables, LIMS connection software, and customer support. Its solutions are applied in environmental monitoring, water testing, in-process bioburden, and sterility release testing. The company also offers RMBNucleus Mold Alarm software and onsite technical training services, facilitating efficient manufacturing and safe release of healthcare products.
RPID’s Geographic footprint
Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with U.S. manufacturing facilities in Lowell, Massachusetts. Globally, the company operates and sells its products in Switzerland, Germany, Japan, the Netherlands, and other international markets.
RPID Corporate Image Assessment
Rapid Micro Biosystems has strengthened its brand reputation through a global distribution agreement with MilliporeSigma in 2025, leveraging a global sales channel to accelerate the adoption of the Growth Direct system. Securing a record multi-system order from a top 20 global biopharma customer validates the platform's ability to meet large-scale manufacturing demands, underscoring its position as a leading automated solution in pharmaceutical microbiology.
Ownership
Rapid Micro Biosystems, Inc. is a publicly traded company with distributed control among institutional investors, company insiders, and the general public. As of February 27, 2026, there are 55 institutional owners and shareholders holding 14,707,310 shares, representing 33.49% ownership. Insider ownership is 5.84% (2.58 million shares). Major institutional owners include Bain Capital Life Sciences Investors, LLC, Vanguard Group Inc, and ABG-WTT Global Life Science Capital Partners GP Ltd, among others.
